Charles Schwab Investment Management Inc. Grows Position in HealthEquity, Inc. (NASDAQ:HQY)

Charles Schwab Investment Management Inc. boosted its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 2.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,002,283 shares of the company's stock after acquiring an additional 21,766 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.17% of HealthEquity worth $66,451,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Advisor Partners II LLC bought a new stake in shares of HealthEquity in the 3rd quarter worth $206,000. Fifth Third Bancorp grew its position in HealthEquity by 36.5% in the 3rd quarter. Fifth Third Bancorp now owns 602 shares of the company's stock worth $44,000 after purchasing an additional 161 shares in the last quarter. Orion Portfolio Solutions LLC increased its stake in HealthEquity by 38.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 4,590 shares of the company's stock valued at $335,000 after buying an additional 1,284 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of HealthEquity by 0.4% during the 3rd quarter. Principal Financial Group Inc. now owns 340,740 shares of the company's stock worth $24,891,000 after buying an additional 1,434 shares in the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in shares of HealthEquity in the 3rd quarter worth approximately $13,221,000. Institutional investors and hedge funds own 99.55% of the company's stock.

HealthEquity Price Performance

NASDAQ:HQY traded up $2.55 during midday trading on Thursday, hitting $78.40. The company had a trading volume of 557,315 shares, compared to its average volume of 595,404. The stock's fifty day moving average price is $80.11 and its 200-day moving average price is $74.93. HealthEquity, Inc. has a 52-week low of $54.09 and a 52-week high of $84.49. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $6.73 billion, a PE ratio of 122.11, a P/E/G ratio of 1.26 and a beta of 0.55.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.42 by $0.08. The firm had revenue of $262.39 million for the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. As a group, research analysts expect that HealthEquity, Inc. will post 2.12 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jon Kessler sold 33,765 shares of the stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the sale, the chief executive officer now directly owns 126,635 shares in the company, valued at approximately $10,106,739.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other HealthEquity news, CEO Jon Kessler sold 33,765 shares of the business's stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares in the company, valued at $10,106,739.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Evelyn S. Dilsaver sold 32,500 shares of the stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the sale, the director now owns 32,123 shares of the company's stock, valued at $2,547,032.67. The disclosure for this sale can be found here. Insiders sold 68,823 shares of company stock valued at $5,482,975 over the last three months. Insiders own 2.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HQY. Barclays lifted their price target on HealthEquity from $84.00 to $104.00 and gave the stock an "overweight" rating in a report on Friday, February 23rd. Royal Bank of Canada boosted their price target on shares of HealthEquity from $90.00 to $92.00 and gave the stock an "outperform" rating in a report on Wednesday, March 20th. JMP Securities initiated coverage on shares of HealthEquity in a report on Thursday, April 4th. They set a "mkt outperform" rating and a $101.00 price objective for the company. Bank of America boosted their target price on shares of HealthEquity from $93.00 to $97.00 and gave the company a "buy" rating in a research note on Wednesday, March 20th. Finally, KeyCorp raised their price target on shares of HealthEquity from $85.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, March 22nd. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.17.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.